NO20092261L - Fremgangsmater for a fremme reparasjon av hjerte ved anvendelse av vekstfaktorer fusjonert til heparin bindingssekvenser - Google Patents

Fremgangsmater for a fremme reparasjon av hjerte ved anvendelse av vekstfaktorer fusjonert til heparin bindingssekvenser

Info

Publication number
NO20092261L
NO20092261L NO20092261A NO20092261A NO20092261L NO 20092261 L NO20092261 L NO 20092261L NO 20092261 A NO20092261 A NO 20092261A NO 20092261 A NO20092261 A NO 20092261A NO 20092261 L NO20092261 L NO 20092261L
Authority
NO
Norway
Prior art keywords
methods
growth factors
binding sequences
heparin binding
heart repair
Prior art date
Application number
NO20092261A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Lee
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO20092261L publication Critical patent/NO20092261L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
NO20092261A 2006-11-13 2009-06-12 Fremgangsmater for a fremme reparasjon av hjerte ved anvendelse av vekstfaktorer fusjonert til heparin bindingssekvenser NO20092261L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85840606P 2006-11-13 2006-11-13
US11/979,708 US9187517B2 (en) 2006-11-13 2007-11-07 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
PCT/US2007/023527 WO2008063424A2 (en) 2006-11-13 2007-11-08 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences

Publications (1)

Publication Number Publication Date
NO20092261L true NO20092261L (no) 2009-08-06

Family

ID=39430287

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092261A NO20092261L (no) 2006-11-13 2009-06-12 Fremgangsmater for a fremme reparasjon av hjerte ved anvendelse av vekstfaktorer fusjonert til heparin bindingssekvenser

Country Status (13)

Country Link
US (2) US9187517B2 (enExample)
EP (1) EP2091550B1 (enExample)
JP (1) JP2010508845A (enExample)
KR (1) KR20090087061A (enExample)
AU (1) AU2007322217A1 (enExample)
BR (1) BRPI0718679A2 (enExample)
CA (1) CA2670830A1 (enExample)
IL (1) IL198708A0 (enExample)
MX (1) MX2009005090A (enExample)
NO (1) NO20092261L (enExample)
NZ (1) NZ577235A (enExample)
RU (1) RU2009122456A (enExample)
WO (1) WO2008063424A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
JP2012093290A (ja) * 2010-10-28 2012-05-17 Sumitomo Bakelite Co Ltd 医療用粒子および生理活性物質の捕捉方法
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US9637531B2 (en) 2012-06-25 2017-05-02 The Brigham And Women's Hospital, Inc Selective cartilage therapy
WO2014004465A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
EP3355907B1 (en) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
EA037848B1 (ru) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
JP2021516966A (ja) 2018-03-09 2021-07-15 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織への生物学的薬物の送達

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US5723331A (en) * 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
CA2261292C (en) * 1996-07-25 2008-09-30 Genzyme Corporation Chondrocyte media formulations and culture procedures
AUPP298498A0 (en) * 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
AU2001288392A1 (en) * 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
CA2496732A1 (en) 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7399831B2 (en) 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
US7429567B2 (en) 2005-01-04 2008-09-30 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences

Also Published As

Publication number Publication date
CA2670830A1 (en) 2008-05-29
KR20090087061A (ko) 2009-08-14
EP2091550A2 (en) 2009-08-26
WO2008063424A3 (en) 2008-09-12
US9187517B2 (en) 2015-11-17
RU2009122456A (ru) 2010-12-20
IL198708A0 (en) 2011-08-01
US9969788B2 (en) 2018-05-15
EP2091550A4 (en) 2009-12-09
US20080138323A1 (en) 2008-06-12
AU2007322217A1 (en) 2008-05-29
US20160024170A1 (en) 2016-01-28
EP2091550B1 (en) 2013-01-02
WO2008063424A2 (en) 2008-05-29
JP2010508845A (ja) 2010-03-25
NZ577235A (en) 2011-12-22
MX2009005090A (es) 2009-07-24
BRPI0718679A2 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
NO20092261L (no) Fremgangsmater for a fremme reparasjon av hjerte ved anvendelse av vekstfaktorer fusjonert til heparin bindingssekvenser
UA99152C2 (ru) Восстановление и регенерация почечной ткани с использованием клеток, полученных с человеческой ткани пупочного канатика
WO2007115175A3 (en) Cyclic natriuretic peptide constructs
CY1120007T1 (el) Αναδιαμορφωση και γλυκοpegυλιωση αυξητικου παραγοντα ινοβλαστης (fgf)
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NO20083793L (no) Antistoffer mot amyloid-beta peptid
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
CY1122134T1 (el) Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
WO2007115182A3 (en) Linear natriuretic peptide constructs
IN2012DN02981A (enExample)
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
NZ581468A (en) Methods of modifying antibodies, and modified antibodies with improved functional properties
RU2011151877A (ru) Пептиды, проникающие в клетку
ATE395924T1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
WO2007125210A3 (fr) Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer ou de l'inflammation
CN102066416A (zh) 肽、拟肽及其衍生物、它们的生产方法以及它们用于制备治疗和/或预防活性的药物组合物的用途
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
ATE556728T1 (de) Gewebeaufbaugerüste mit homingfaktoren
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
ATE439098T1 (de) Implantierbare prothese zur reparatur von herniendefekten
MX2010010177A (es) Fragmentos de beta timosina mejorada.
EA201071226A1 (ru) Искусственный каркас белка
ATE443725T1 (de) Nichtaktivierte polypeptide mit einer geweberegenerationsfunktion und verfahren zu ihrer herstellung
WO2008133929A3 (en) Cell permeable miniature proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application